Therapeutic EBV vaccines have been designed and tested in nasopharyngeal carcinoma (NPC) mainly aimed at EBNA1, LMP2, and have shown immunogenicity by inducing activated CD4+ and CD8+ T cells responses (166). This evidence concerns the gene CD8A and nasopharyngeal carcinoma.